Featured Research

from universities, journals, and other organizations

Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer, study finds

Date:
July 13, 2011
Source:
American College of Radiology
Summary:
Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to new research.

Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in the July 14 issue of the New England Journal of Medicine. This largest randomized trial of its kind enrolled nearly 2,000 men at low and intermediate risk of prostate cancer progression and followed their health status for more than nine years (October 1994 to April 2001) at 212 centers in the United States and Canada.

As trial co-principal investigator and RTOG Genitourinary Cancer Committee Co-Chair William Shipley, M.D. (Massachusetts General Hospital, Boston) explains, "Vigilant, long-term follow up of the enrolled patients was required due to the indolent nature of prostate cancer. With the introduction of prostate-specific antigen (PSA) testing, early detection of the disease has significantly increased; therefore, understanding the best treatment options for men with early-stage cancer is critically important." It is estimated that about 240,890 Americans will be diagnosed with prostate cancer in 2011 and almost 9 out of 10 will have early-stage disease.

All study participants had early, localized, PSA-diagnosed tumors with PSA levels of < 20. Further analysis of study data identified risk subgroups of low risk (Gleason score < 6, PSA level < 10 and clinical stage < T2a) or intermediate risk (Gleason score =7; or Gleason score < 6 with either PSA >10 to < 20 or clinical stage T2b).

Male hormones (androgens), the most common of which is testosterone, fuel the growth of prostate cancer cells. Therapy that decreases the body's levels of androgens (in this study, four months of ADT starting two months prior to radiation therapy) removes the strongest growth factor for prostate cancer cells. The authors report that adding short-term ADT to radiation therapy significantly improved the overall survival rate at 10 years from 57 percent to 62 percent. Furthermore, the radiation therapy plus short-term ADT arm was associated with 4 percent fewer prostate cancer-related deaths compared with the radiation therapy-alone arm (8 percent vs. 4 percent). A particularly important finding was that the reduction in disease-specific deaths was accounted for mostly by the intermediate-risk study participants in the radiation therapy plus ADT arm (10 percent vs. 3 percent in radiation only arm at 10 years) while no reduction in deaths was seen among low-risk participants at 10 years.

"These findings have tremendous significance for improving both clinical care and the utilization of health care resources." says trial co-principal investigator and lead author Christopher U. Jones, M.D. (Radiological Associates of Sacramento, Sacramento, Calif.). "We now have strong scientific evidence that adding short-term ADT to radiation therapy benefits intermediate-risk, but not low-risk, patients with early-stage prostate cancer. These benefits were achieved with a mild increase in patient-reported erectile dysfunction at one year but no increase in observed long-term bowel or bladder toxicities."

RTOG Genitourinary Cancer Committee Chair and co-author Howard Sandler, M.D., (Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles) comments, "In addition to establishing short-term ADT in combination with radiation therapy as the new standard of care for men with intermediate-risk prostate cancer, the results also suggest a biological interaction between the two therapies, given that several randomized trials of surgery and short-term ADT did not show a benefit in outcome."

The authors note that the higher radiation dose and new treatment technology being employed today with demonstrated higher treatment efficacy could potentially provide the same or greater benefit as the addition of short-term ADT. "RTOG launched a trial in 2009 (see RTOG 0815) to examine the role of short-term ADT combined with modern radiotherapy techniques for men with intermediate-risk prostate cancer," says Walter J. Curran, Jr., M.D. (Winship Cancer Institute of Emory University, Atlanta), RTOG Group Chair. "The results of the RTOG 0815 trial will build on the important knowledge gained from this landmark study findings."

This study was supported by grants from the National Cancer Institute.

Authors Christopher U. Jones, MD; Radiological Associates of Sacramento Daniel Hunt, PhD; RTOG Statistical Center David G. McGowan, MB, ChB; Cross Cancer Institute, Department of Radiation Oncology (emeritus) Mahul B. Amin, MD; Cedars-Sinai Medical Center, Department of Pathology and Laboratory Medicine Michael P. Chetner, MD; University of Alberta, Division of Urology, Department of Surgery Deborah B. Bruner, RN, PhD; University of Pennsylvania, School of Nursing Mark H. Leibenhaut, MD; Radiological Associates of Sacramento Siraj M. Husain, MD; Tom Baker Cancer Centre, Department of Radiation Oncology Marvin Rotman, MD; SUNY Health Science Center Brooklyn, Department of Radiation Oncology Luis Souhami, MD; McGill University, Department of Radiation Oncology Howard M. Sandler, MD; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Department of Radiation Oncology William U. Shipley, MD; Massachusetts General Hospital, Department of Radiation Oncology.


Story Source:

The above story is based on materials provided by American College of Radiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Radiology. "Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer, study finds." ScienceDaily. ScienceDaily, 13 July 2011. <www.sciencedaily.com/releases/2011/07/110713182212.htm>.
American College of Radiology. (2011, July 13). Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer, study finds. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/07/110713182212.htm
American College of Radiology. "Short-term hormone therapy plus radiation therapy increases survival for men with early-stage prostate cancer, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/07/110713182212.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins